Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria~1. Written informed consent prior to the performance of any study-related activity.~2. Patients 18 years and older with an average of ≥ 2 nocturnal voids per night as determined by a 3 day frequency-volume chart during the screening period.~Exclusion Criteria:~Males:~1. Clinical suspicion of bladder outlet obstruction and/or urine flow \< 5 ml/s. If medical history and/or physical examination suggest bladder outlet obstruction, uroflowmetry should be performed to confirm the diagnosis~2. Surgical treatment for bladder outlet obstruction/benign prostatic hyperplasia performed within the past 6 months~   Females:~3. Pregnancy. Females of reproductive age must have documentation of a reliable method of contraception.~4. Use of pessary for pelvic prolapse.~5. Unexplained pelvic mass.~   Males and Females:~6. Clinical suspicion of urinary retention and/or post void residual volume \> 150 ml. If medical history and/or physical examination suggest urinary retention, bladder ultrasound or catheterization should be performed to confirm the diagnosis.~7. Current or past urologic malignancy (e.g., bladder cancer, prostate cancer).~8. Clinical evidence of current genitourinary tract pathology that could interfere with voiding.~9. History of neurogenic detrusor activity (previously known as detrusor hyperreflexia).~10. Suspicion or evidence of cardiac failure.~11. Uncontrolled hypertension.~12. Uncontrolled diabetes mellitus.~13. Renal insufficiency. Serum creatinine must be within normal limits and estimated glomerular filtration rate (eGFR) \>=60 mL/min.~14. Active hepatic and/or biliary disease. Aspartate transaminase (AST) or alanine transaminase (ALT) should not be \>2 times the upper limit of normal. Total bilirubin should not be \> 1.5 mg/dL.~15. Hyponatremia. Serum sodium level must be within normal limits~16. Syndrome of Inappropriate antidiuretic hormone secretion (SIADH).~17. Diabetes insipidus (urine output \> 40 ml/kg over 24 hours) as determined by the 3-day voiding diary.~18. Psychogenic or habitual polydipsia~19. Obstructive sleep apnea~    Other~20. Known alcohol or substance abuse~21. Work or lifestyle potentially interfering with regular nighttime sleep (e.g., shift workers)~22. Previous desmopressin treatment for nocturia.~23. Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity or language barrier that, in the judgment of the investigator, could impair patient participation in the trial.~24. Use of loop diuretics (furosemide, torsemide, ethacrynic acid). Other classes of diuretics (thiazides, triamterene, chlorthalidone, amiloride, indapamide) were permitted, either as monotherapy or combination therapy. Subjects using a diuretic were to be encouraged to take it in the morning, if medically feasible.~25. Use of any other investigational drug within 30 days of screening.~Concomitant Medications~The following medications are permitted provided that the subject has been on a stable dose for the 3 months prior to the screening date (i.e. treatment has not been initiated or discontinued and there has been no change in dose):~* Alpha-blockers: Cardura (doxazosin); Flomax (tamsulosin); Hytrin (terazosin); Uroxatral (alfuzosin)~* 5 alpha-reductase inhibitors: Avodart (dutasteride); Proscar (finasteride)~* Antispasmodic, anticholinergic, antimuscarinic therapy for overactive bladder: Detrol, Detrol LA (tolterodine); Ditropan, Ditropan XL (oxybutynin); Enablex (darifenacin); Levsin(hyoscyamine); Oxytrol transdermal (oxybutynin); Sanctura (trospium); Vesicare (solifenacin)~* Sedative/hypnotic medications for sleep disorders~* Selective serotonin and mixed norepinephrine/serotonin reuptake inhibitors: Celexa (citalopram); Cymbalta (duloxetine); Effexor (venlafaxine); Lexapro (escitalopram); Paxil(paroxetine); Prozac (fluoxetine); Zoloft (sertraline)~* Chronic use of nonsteroidal anti-inflammatory agents~* Diabinese (chlorpropamide)~* Carbamazepine (carbatrol/tegretol)~* Amiodarone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants took a placebo 'melt' for 28 days to complete part 1 of the study. In part 2, placebo patients were randomized to one of the other 4 treatment arms based on assignments predetermined at the initial randomization, to receive active desmopressin melt for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
- desmopressin melt 10 μg (Type: EXPERIMENTAL): Participants took desmopressin melt 10 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
- desmopressin melt 25 μg (Type: EXPERIMENTAL): Participants took desmopressin melt 25 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
- desmopressin melt 50 μg (Type: EXPERIMENTAL): Participants took desmopressin melt 50 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
- desmopressin melt 100 μg (Type: EXPERIMENTAL): Participants will take desmopressin melt 100 μg for 28 days to complete part 1 of the study. Participants will continue on this dose in part 2 of the study for between 1-6 months (until the database for part 1 is locked and treatment is unblinded).

Based on this trial design, predict the completion outcome and termination type (if applicable).